Evidence map›Paper›PMID 34109161›Full record

ArticleFrontiers in bioengineering and biotechnology2021

Further Biochemical Profiling of

Suhad A A Al-Salihi, Ian D Bull, Raghad Al-Salhi, Paul J Gates, Kifah S M Salih, Andy M Bailey, Gary D Foster

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Genomic Based Analysis of the Biocontrol SpeciesJournal of fungi (Basel, Switzerland) · 2023
    Article
  2. Further Biochemical Profiling ofFrontiers in bioengineering and biotechnology · 2021
    Article
  3. Mycology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Suhad A A Al-SalihiSchool of Biological Sciences, University of Bristol, Bristol, United Kingdom.
Ian D BullSchool of Chemistry, University of Bristol, Bristol, United Kingdom.
Raghad Al-SalhiChemistry Department, University of Mustansiriyah, Baghdad, Iraq.
Paul J GatesSchool of Chemistry, University of Bristol, Bristol, United Kingdom.
Kifah S M SalihCollege of Arts and Sciences, Qatar University, Doha, Qatar.
Andy M BaileySchool of Biological Sciences, University of Bristol, Bristol, United Kingdom.
Gary D FosterSchool of Biological Sciences, University of Bristol, Bristol, United Kingdom.
University of Bristol · GBMustansiriyah University · IQQatar University · QA

Funding

Medical Research Council MR/N029909/1
6 · The paper itself

Abstract

Natural products with novel chemistry are urgently needed to battle the continued increase in microbial drug resistance. Mushroom-forming fungi are underutilized as a source of novel antibiotics in the literature due to their challenging culture preparation and genetic intractability. However, modern fungal molecular and synthetic biology tools have renewed interest in exploring mushroom fungi for novel therapeutic agents. The aims of this study were to investigate the secondary metabolites of nine basidiomycetes, screen their biological and chemical properties, and then investigate the genetic pathways associated with their production. Of the nine fungi selected,

Indexed as

biosynthetic gene clustergenomeHypholoma fascicularemetabolometerpene

Identifiers

PMID34109161
PMCPMC8181146
OpenAlexW3159229903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.